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inappropriate HER2 testing.
The authors also estimated, from a database derived from the unreferenced multi-centric study, the sensitivity and specificity of IHC as used in France.
Study designs and other criteria for inclusion in the review
The criteria for inclusion were not reported. One major source of evidence was unpublished. The rest were published studies.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The total number of studies included was unclear. There appears to have been at least six studies.
Methods of combining primary studies
The studies were combined using narrative methods. The authors used the primary studies to create databases from which to derive parameter estimates.
Investigation of differences between primary studies
Results of the review
At metastatic relapse, HER2 testing was never reported as being impossible. Therefore, the only reason for patients with HER2 amplified tumour not be given trastuzumab at first metastatic relapse was because they were identified as false negatives.
Seventy-four per cent of IHC scores were 0 or 1+, 2% were 2+ and 24% were 3+ for patients who relapsed within 10 years after diagnosis.
All scores were 0 or 1+ when relapse occurred after 10 years.
The sensitivity of IHC compared with FISH was 0.88 and the specificity was 0.91.
Measure of benefits used in the economic analysis
Two summary measures of health outcome were used in the economic analysis. The first was the number of patients correctly managed (defined as the false-negatives avoided) and the second was the number of patients correctly managed (false-positives avoided).
